Uprosertib
- Generic Name
- Uprosertib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C18H16Cl2F2N4O2
- CAS Number
- 1047634-65-0
- Unique Ingredient Identifier
- ZXM835LQ5E
- Background
Uprosertib has been used in trials studying the treatment of Cancer, Melanoma, Solid Tumours, Cervical Cancer, and HER2/Neu Negative, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2013-11-21
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 25
- Registration Number
- NCT01989598
- Locations
- π¨π¦
University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
π¨π¦Tom Baker Cancer Centre, Calgary, Alberta, Canada
π¨π¦Cross Cancer Institute, Edmonton, Alberta, Canada
Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma
- Conditions
- Interventions
- First Posted Date
- 2013-11-08
- Last Posted Date
- 2020-02-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 42
- Registration Number
- NCT01979523
- Locations
- πΊπΈ
M D Anderson Cancer Center, Houston, Texas, United States
π«π·Institut Curie Paris, Paris, France
πΊπΈEmory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-09-05
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 26
- Registration Number
- NCT01935973
- Locations
- πΊπΈ
University of New Mexico Cancer Center, Albuquerque, New Mexico, United States
πΊπΈUniversity of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States
πΊπΈWashington University School of Medicine, Saint Louis, Missouri, United States
Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-07-18
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 27
- Registration Number
- NCT01902173
- Locations
- πΊπΈ
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
πΊπΈOhio State University Comprehensive Cancer Center, Columbus, Ohio, United States
πΊπΈClackamas Radiation Oncology Center, Clackamas, Oregon, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.